#1 Clinical Trials Search in Europe

Prx005

PRX005, also known as BMS-986446, is an innovative anti-MTBR Tau monoclonal antibody currently being studied in clinical trials for the treatment of early Alzheimer’s Disease. This article explores the ongoing Phase 2 clinical trial, known as TargetTau-1, which aims to evaluate the efficacy, safety, and tolerability of PRX005 in patients with early-stage Alzheimer’s. The study focuses on assessing changes in cognitive function and brain tau deposition, offering hope for potential breakthroughs in Alzheimer’s treatment.

Table of Contents

What is PRX005?

PRX005 is a new medication being studied for the treatment of early Alzheimer’s disease. It is also known by its sponsor product code BMS-986446 or as an Anti-MTBR-Tau mAb (monoclonal antibody)[1]. This means it’s a type of antibody that targets a specific part of the tau protein in the brain, which is believed to play a role in Alzheimer’s disease.

How PRX005 Works

PRX005 is designed to target the MTBR (microtubule binding region) of the tau protein. In Alzheimer’s disease, tau proteins can accumulate and form tangles in the brain, which are thought to contribute to the progression of the disease. By targeting these tau proteins, PRX005 aims to slow down or potentially halt the progression of early Alzheimer’s disease[1].

Current Research on PRX005

PRX005 is currently being studied in a Phase 2 clinical trial called TargetTau-1. This is a global study designed to evaluate how well PRX005 works and how safe it is for people with early Alzheimer’s disease[1]. The study is:

  • Randomized: Participants are randomly assigned to either receive PRX005 or a placebo (a substance with no active medication).
  • Double-blind: Neither the participants nor the researchers know who is receiving PRX005 or the placebo during the study.
  • Placebo-controlled: Some participants receive a placebo to compare the effects with those who receive PRX005.

Who Can Participate in the PRX005 Study?

The study is looking for people with early Alzheimer’s disease. To be eligible, participants must meet several criteria, including[1]:

  • Having mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s disease dementia. This means people who are starting to have memory problems or other cognitive issues, but can still perform most daily activities.
  • Scoring between 0.5 and 1.0 on the Global Clinical Dementia Rating (CDR) scale. This scale measures the severity of dementia symptoms.
  • Having evidence of Alzheimer’s disease pathology in the brain. This might be determined through brain scans or other tests.
  • Showing impairment in memory tests, specifically scoring at least one standard deviation below the age-adjusted mean on a specific memory test (Wechsler Memory Scale IV-Logical Memory Subtest II).
  • Having a score of 22 to 30 on the Mini Mental Status Examination (MMSE). This is a test that assesses cognitive function.

There are also several factors that would exclude someone from participating in the study, such as having other conditions that affect cognition, or not being able to undergo certain types of brain scans[1].

Study Objectives and Measurements

The main goal of the study is to see how PRX005 affects thinking abilities and general functioning in people with early Alzheimer’s disease. Researchers will measure this using a scale called the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) after 76 weeks of treatment[1].

The study will also look at several other factors, including[1]:

  1. Changes in tau protein buildup in the brain, measured using PET scans (a type of brain imaging).
  2. Changes in cognitive function and daily living activities, measured by various tests and scales.
  3. The safety of PRX005 and how well patients tolerate it.

Potential Benefits of PRX005

While it’s important to note that PRX005 is still in the research phase and its benefits are not yet proven, the hope is that it could potentially[1]:

  • Slow down the progression of early Alzheimer’s disease
  • Improve or maintain cognitive function in people with early Alzheimer’s
  • Help people with early Alzheimer’s maintain their ability to perform daily activities

However, more research is needed to determine if PRX005 is safe and effective for treating early Alzheimer’s disease. The ongoing clinical trial will provide valuable information about this potential new treatment.

Aspect Details
Drug Name PRX005 (BMS-986446)
Drug Type Anti-MTBR Tau Monoclonal Antibody
Trial Phase Phase 2
Target Condition Early Alzheimer’s Disease
Main Objective Change in thinking and general functioning at Week 76
Primary Endpoint Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score
Key Secondary Endpoints Change in brain tau deposition, integrated Alzheimer’s Disease Rating Scale (iADRS) score
Administration Intravenous injection
Key Inclusion Criteria MCI due to AD or mild AD dementia, CDR score 0.5-1.0, MMSE score 22-30
Key Exclusion Criteria Other conditions affecting cognition, contraindications to PET or MRI imaging

FAQ

  • What is PRX005 and how does it work? PRX005 is an anti-MTBR Tau monoclonal antibody designed to target the tau protein in the brain. In Alzheimer's Disease, tau proteins can build up and form tangles, contributing to cognitive decline. PRX005 aims to reduce this tau buildup, potentially slowing down the progression of the disease.
  • Who is eligible to participate in the PRX005 clinical trial? The trial is open to individuals with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia. Participants must have a Global Clinical Dementia Rating score of 0.5 to 1.0, evidence of Alzheimer's pathology, and a Mini Mental Status Examination score between 22 and 30, among other criteria.
  • How long does the PRX005 clinical trial last? The main treatment period of the trial lasts for 76 weeks (about 1.5 years). The primary endpoint, which measures changes in thinking and general functioning, is assessed at the end of this 76-week period.
  • What are the main objectives of the PRX005 clinical trial? The main objective is to measure changes in thinking and general functioning using the Clinical Dementia Scale Sum of Boxes (CDR-SB) at Week 76. Secondary objectives include measuring tau buildup in the brain using PET scans and assessing the drug's effect on delaying symptom progression using various cognitive and functional scales.
  • How is PRX005 administered to patients in the trial? PRX005 is administered as a solution for injection via intravenous route. The exact dosing schedule is not specified in the provided information, but the drug concentration is 50 mg/ml.

Ongoing Clinical Trials on Prx005

  • Study of BMS-986446 for Early Alzheimer’s Disease Patients

    Not recruiting

    2 1
    Investigated drugs:
    Belgium Spain Sweden

Glossary

  • Alzheimer's Disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, PRX005 is designed to target tau proteins in the brain.
  • Tau Protein: A protein that can form abnormal tangles in the brains of people with Alzheimer's disease, contributing to the death of brain cells.
  • Clinical Dementia Rating Scale Sum of Boxes (CDR-SB): A tool used to measure cognitive and functional performance in people with Alzheimer's disease.
  • Positron Emission Tomography (PET) Scan: An imaging test that uses a radioactive substance to show how organs and tissues are working. In this trial, it's used to measure tau buildup in the brain.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, including memory and thinking skills.
  • Mini Mental Status Examination (MMSE): A widely used test of cognitive function among older adults; it includes questions on orientation, registration, attention and calculation, recall, and language.
  • Integrated Alzheimer's Disease Rating Scale (iADRS): A combined scale that measures both cognitive and functional aspects of Alzheimer's disease progression.

References

  1. http://clinicaltrials.eu/trial/study-of-bms-986446-for-early-alzheimers-disease-patients/